Core Viewpoint - The company is currently not involved in the brain-computer interface sector but will closely monitor developments in this industry [1] Group 1: AI Technology in Drug Development - The company utilizes AI technology in its innovative drug research, specifically in AIDD (Artificial Intelligence Drug Discovery) and CADD (Computer-Aided Drug Design) [1] - The company has developed its own AI platform, known as the Smart Drug AI platform, which can be applied to toxicity prediction as well as activity and drug-likeness prediction [1] Group 2: Organoid Platform and Drug Development Services - The company's organoid platform provides drug development technical services, including drug screening, efficacy evaluation, and safety assessment [1] - This platform aims to enhance the precision and efficiency of drug development processes [1]

格隆汇1月13日丨康龙化成(300759.SZ)公布，预计2025年营业收入1,387,162.56万元–1,423,989.89万元， 比上年同期增长13%–16%，归属于上市公司股东的净利润161,401.57万元–168,574.98万元，比上年同期 下降6%–10%，归属于上市公司股东的扣除非经常性损益后的净利润150,676.29万元–156,215.86万元， 比上年同期增长36%–41%。 公司坚定地推行"全流程、一体化、国际化、多疗法"的核心战略，以客户需求为导向，深化全球化布 局，强化技术平台建设。2025年，公司预计营业收入同比增长13%-16%、归属于上市公司股东的扣除非 经常性损益后的净利润同比增长36%-41%、经调整的非《国际财务报告准则》下归属于上市公司股东的 净利润同比增长10%-15%。按业绩预告中位值测算，2025年第四季度，公司营业收入同比增长 14.79%、归属于上市公司股东的扣除非经常性损益后的净利润同比增长54.09%、经调整的非《国际财 务报告准则》下归属于上市公司股东的净利润同比增长16.36%。 如上所述，报告期内归属于上市公司股东的非经常性损益为人民币11, ...

（文章来源：每日经济新闻） 每经AI快讯，1月13日，药明康德A股上涨7.9%，创5个月来最大涨幅；药明康德H股上涨9.7%，创2025 年2月以来最大涨幅。 ...

消息面上，1月12日，药明康德发布公告，预期本公司(连同其子公司统称为：本集团)于截至2025年12 月31日止年度(本期)营业收入及归属于本公司股东的净利润相比2024年年度同期(上年同期)将取得上 升。公司预计本期实现归属于本公司股东的净利润约人民币191.51亿元，同比增长约102.65%，其中包 含了出售联营公司部分股权以及剥离部分业务所获得的投资收益；本期基本每股收益预计约人民币6.70 元╱股，同比增长约104.27%。 药明康德（603259）(02359)盈喜后高开逾4%，截至发稿，涨4.69%，报116港元，成交额3112.34万港 元。 ...

Core Insights - Apple has announced a multi-year agreement with Google to upgrade Siri using the Gemini model, enhancing personalized smart features, while Elon Musk criticized the collaboration for potentially leading to excessive power concentration [2] - Tempus AI forecasts an 83% revenue surge in 2025, with total contract value exceeding $1.1 billion, showcasing significant technological advantages and market expansion in the medical AI sector [2] - WuXi AppTec anticipates a net profit growth of approximately 102.65% in 2025, significantly exceeding market expectations, driven by its leading position in global pharmaceutical R&D services and sustained order growth [2] - Xpeng Motors has set a delivery target of 550,000 to 600,000 vehicles for 2026, representing a year-on-year increase of 28.1% to 39.7%, with plans to launch four new SUV models [2] - Alibaba is recommended for gradual accumulation by JPMorgan, citing short-term profit margin pressures due to investments in food delivery, e-commerce, and AI applications, but expects accelerated revenue growth from Alibaba Cloud [2] Greater China Company News - Rongchang Biopharmaceutical has signed an exclusive licensing agreement with AbbVie for the dual-specific antibody drug RC148, receiving an upfront payment of $650 million and potential milestone payments up to $4.95 billion [4] - TSMC projects a net profit of NT$475.2 billion (approximately $15.02 billion) in Q4 2025, a 27% year-on-year increase, driven by rising global AI infrastructure demand and the release of 3nm process capacity [4] - Kweichow Moutai plans to adjust the factory prices of several products for the first time in three years, with significant price reductions for "Moutai Boutique" and "Moutai 15-Year" [4] - Ctrip mistakenly sent a mass layoff notice, which was clarified as an internal error, not indicative of a company-wide layoff [4] Americas Company News - NVIDIA and Eli Lilly plan to jointly invest $1 billion over five years to establish an AI drug development lab, while also collaborating with Thermo Fisher on AI-driven lab automation solutions [6] - Meta is set to announce layoffs affecting about 10% of its Reality Labs staff, reallocating funds from virtual reality to wearable devices, and plans to invest billions in expanding data center infrastructure [6] - Tesla's stock is under pressure following a fatal accident involving a semi-truck, although EU plans to replace punitive tariffs with minimum import prices may alleviate cost pressures in the European market [6] - Amazon's fine from Italy's antitrust authority has been reduced from €1.128 billion to €752.4 million, while also reforming its return policy for high-value items [6] Asia-Pacific Company News - Samsung Electronics is collaborating with T-Mobile on retail media innovations and is set to release the Galaxy S26 Ultra with improved satellite communication features [10] - SK Hynix is experiencing rising DRAM prices, with 32GB memory prices reaching several thousand yuan, and is expected to achieve a profit margin of 82% [10] - LG Energy is projected to incur a loss of $83.8 million in Q4 2025, while planning to release low-cost OLED TVs to expand market share [10] - Hyundai has ordered 30,000 Boston Dynamics robots to enhance smart manufacturing capabilities [10] Europe and Oceania Company News - European satellite communications company has ordered an additional 340 OneWeb low Earth orbit satellites from Airbus, bringing the total to 440, expected to enhance global broadband communications [12] - BHP has no plans to make a takeover bid for Glencore amid renewed merger talks between Rio Tinto and Glencore [12] - Rio Tinto is considering acquiring Glencore's coal business as part of its renewed merger discussions [12] - Mercedes-Benz expects a 9% decline in global sales to 1.8 million units in 2025, with a significant drop in the Chinese market [12]

登录新浪财经APP 搜索【信披】查看更多考评等级 北京昭衍新药研究中心股份有限公司（以下简称"昭衍新药"、"公司"）于2024年12月20日召开第四届董 事会第十一次会议，审议通过了《关于公司与专业投资机构合作参与投资基金的议案》，同意公司或其 指定子公司以不超过800万元人民币投资参与投资北脑一期（北京）股权投资中心（有限合伙）（以下 简称"本基金"、"有限合伙"）。北京崇德英盛投资管理有限公司为本基金的普通合伙人、执行事务合伙 人，并担任本基金的基金管理人。具体内容详见公司于2024年12月21日在上海证券交易所网站 （www.sse.com.cn）及指定信息披露媒体《上海证券报》披露的《昭衍新药关于与专业投资机构合作参 与投资基金的公告》（公告编号：2024-059）。 2025年8月，公司全资子公司北京昭衍管理科技有限公司（以下简称"昭衍管理"）与北京崇德英盛投资 管理有限公司及参与本基金的其他合伙人共同签署了《北脑一期（北京）股权投资中心（有限合伙）合 伙协议》。合伙企业募集资金总额为9,000万元，昭衍管理作为有限合伙人以自有资金认缴出资800万元 认购8.89%的基金份额。具体内容详见公司于20 ...

Core Viewpoint - WuXi AppTec (603259.SH, 02359.HK) has raised its revenue forecast for 2025 for the third time, expecting approximately 45.456 billion yuan in revenue, a year-on-year increase of about 15.84%, with a significant net profit forecast of around 19.151 billion yuan, representing a 102.65% increase year-on-year, marking a historical high for the company [1][3]. Group 1 - The company expects 2025 revenue to reach approximately 45.456 billion yuan, with a year-on-year growth of about 15.84%, and a 21.40% increase in revenue from continuing operations [1]. - The previous revenue forecast was adjusted from 42.5-43.5 billion yuan to 43.5-44 billion yuan during the Q3 report [1]. - The anticipated net profit for 2025 is approximately 19.151 billion yuan, which is a historical high and represents a year-on-year increase of about 102.65% [1][3]. Group 2 - The company focuses on a unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing) business model, enhancing production efficiency and expanding capabilities to drive steady business growth [3]. - Significant net profit contributions are expected from the sale of assets, including approximately 4.161 billion yuan from the sale of shares in WuXi AppTec's subsidiary and about 1.434 billion yuan from the sale of 100% equity in two clinical research companies, totaling nearly 5.6 billion yuan in net gains [3]. - The asset sales align with the company's strategy to focus on the CRDMO business model, providing funding support for global capacity expansion [3].

Core Viewpoint - WuXi AppTec (药明康德) anticipates an increase in revenue and net profit for the fiscal year ending December 31, 2025, compared to the same period in 2024, driven by its integrated CRDMO business model and strategic asset sales [1][2]. Group 1: Financial Performance - The company expects to achieve revenue of approximately RMB 45,456.17 million, representing a year-on-year growth of about 15.84%, with a 21.40% increase in revenue from continuing operations [1]. - Adjusted net profit attributable to shareholders is projected to be around RMB 14.957 billion, reflecting a year-on-year growth of approximately 41.33% [1]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to be about RMB 13.241 billion, with a year-on-year increase of approximately 32.56% [1]. - The total net profit attributable to shareholders is anticipated to be around RMB 19.151 billion, showing a significant year-on-year growth of approximately 102.65% [1]. - Basic earnings per share are expected to be approximately RMB 6.70, representing a year-on-year increase of about 104.27% [1]. Group 2: Business Strategy and Operations - The company continues to focus on its unique "integrated, end-to-end" CRDMO business model, enhancing capabilities and building new production capacity to meet customer demands [2]. - The impact of non-recurring gains on net profit primarily stems from the sale of a portion of its stake in WuXi XDC Cayman Inc., expected to yield a net gain of approximately RMB 4.161 billion, and the sale of 100% stakes in Shanghai Kangde Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd., expected to yield a net gain of approximately RMB 1.434 billion [2].

智通财经APP获悉，2026年1月12日晚间，药明康德(603259.SH/02359)发布了2025年度业绩预增公告。公司预计2025年全年营业收入约454.56亿元，创下历 史新高。 除了创记录的营业收入，药明康德的利润层面，三个口径下关键指标亦实现高于营收的增速攀升，经调整non-IFRS归母净利润、归母净利润及扣非后归母净 利润，分别同比增长约41.33%、102.65%及32.56%。 此前，药明康德已在三季度时第二次上调了全年经营目标。公司表示，紧抓客户需求、业务模式和管理执行的确定性，进一步上调全年业绩指引，预计2025 年持续经营业务重回双位数增长，增速上调至17~18%，公司整体收入上调至435~440亿元。 ...

根据统计，上市以来的七年时间里，药明康德通过现金分红、回购及注销股份的方式，累计回馈投资者 达到200亿元，超过了公司过去七年累计净利润的40%。 在归母净利润、每股收益达成新高的背景下，药明康德2025年度现金分红亦有望创下新高。按照此前， 公司在三季度业绩交流会上曾表示，上市以来一贯维持约30%的现金分红比例。根据本次预告的归母净 利润测算，2025年度现金分红总额预计将突破57亿元。 智通财经APP获悉，1月12日晚间，药明康德(603259.SH/02359)披露了其2025年度预增公告。公告显 示，公司预计全年营业收入约456.56亿元，同比增长约15.84%；其中持续经营业务收入同比增长约 21.4%。盈利方面，经调整non-IFRS归母净利润、归母净利润、扣非归母净利润分别同比增长约 41.33%、102.65%及32.56%，基本每股收益同样翻倍达到6.7元。 ...